Simplify Asset Management Inc. Sells 12,586 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Simplify Asset Management Inc. trimmed its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 49.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 12,907 shares of the company’s stock after selling 12,586 shares during the quarter. Simplify Asset Management Inc.’s holdings in Establishment Labs were worth $586,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mudita Advisors LLP lifted its position in shares of Establishment Labs by 49.7% during the fourth quarter. Mudita Advisors LLP now owns 142,400 shares of the company’s stock worth $3,687,000 after purchasing an additional 47,284 shares during the last quarter. Stableford Capital II LLC bought a new stake in Establishment Labs during the 1st quarter valued at about $1,568,000. BNP Paribas Financial Markets boosted its position in Establishment Labs by 32,968.7% in the 1st quarter. BNP Paribas Financial Markets now owns 97,222 shares of the company’s stock valued at $4,949,000 after buying an additional 96,928 shares during the period. Swiss National Bank grew its stake in Establishment Labs by 13.6% in the 1st quarter. Swiss National Bank now owns 37,500 shares of the company’s stock worth $1,909,000 after acquiring an additional 4,500 shares in the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of Establishment Labs during the first quarter worth approximately $263,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. Citigroup lifted their target price on Establishment Labs from $41.00 to $45.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Stephens reissued an “overweight” rating and set a $68.00 price target on shares of Establishment Labs in a research report on Wednesday, August 7th. Finally, Mizuho lifted their price objective on Establishment Labs from $65.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, June 6th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.60.

Establishment Labs Stock Up 3.9 %

NASDAQ:ESTA opened at $43.96 on Friday. The company’s 50-day simple moving average is $43.67 and its 200-day simple moving average is $47.63. The company has a debt-to-equity ratio of 4.30, a quick ratio of 2.91 and a current ratio of 4.44. Establishment Labs Holdings Inc. has a fifty-two week low of $16.96 and a fifty-two week high of $60.12. The stock has a market capitalization of $1.21 billion, a P/E ratio of -14.00 and a beta of 1.20.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). The firm had revenue of $44.12 million during the quarter, compared to analyst estimates of $43.10 million. Establishment Labs had a negative net margin of 54.97% and a negative return on equity of 220.67%. Establishment Labs’s revenue was down 9.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.65) earnings per share. On average, equities analysts anticipate that Establishment Labs Holdings Inc. will post -2.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Establishment Labs news, CEO Quiros Juan Jose Chacon sold 6,839 shares of Establishment Labs stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $45.30, for a total transaction of $309,806.70. Following the completion of the sale, the chief executive officer now directly owns 218,896 shares in the company, valued at approximately $9,915,988.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 14,346 shares of company stock worth $647,806. 11.44% of the stock is owned by company insiders.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.